Advertisement

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

  • Michela Del Prete
  • François-Alexandre Buteau
  • Frédéric Arsenault
  • Nassim Saighi
  • Louis-Olivier Bouchard
  • Alexis Beaulieu
  • Jean-Mathieu BeauregardEmail author
Original Article
  • 219 Downloads

Abstract

Purpose

Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297).

Methods

PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177Lu-octreotate with quantitative SPECT/CT-based dosimetry. The IA was personalized according to the glomerular filtration rate and the body surface area for the first cycle, and according to the prior renal Gy/GBq for the subsequent cycles. The prescribed renal absorbed dose of 23 Gy was reduced by 25–50% in case of significant renal or haematological impairment. Responders were allowed to receive consolidation or maintenance cycles, for each of which 6 Gy to the kidney were prescribed. We simulated the empiric PRRT regime by fixing the IA at 7.4 GBq per cycle, with the same percentage reductions as above. Radiological, molecular imaging, biochemical, and quality of life responses, as well as safety, were assessed.

Results

Fifty-two patients underwent 171 cycles. In 34 patients who completed the induction course, a median cumulative IA of 36.1 (range, 6.3–78.6) GBq was administered, and the median cumulative kidney and maximum tumour absorbed doses were 22.1 (range, 8.3–24.3) Gy and 185.7 (range: 15.2–443.1) Gy respectively. Compared with the simulated fixed-IA induction regime, there was a median 1.26-fold increase (range, 0.47–2.12 fold) in the cumulative maximum tumour absorbed dose, which was higher in 85.3% of patients. In 39 assessable patients, the best objective response was partial response in nine (23.1%), minor response in 14 (35.9%), stable disease in 13 (33.3%) and progressive disease in three patients (7.7%). In particular, 11 of 13 patients (84.6%) with pancreatic NET had partial or minor response. The global health status/quality of life score significantly increased in 50% of patients. Acute and subacute side-effects were all of grade 1 or 2, and the most common were nausea (in 32.7% of patients) and fatigue (in 30.8% of patients) respectively. Subacute grade 3 or 4 toxicities occurred in less than 10% of patients, with the exception of lymphocytopenia in 51.9% of patients, without any clinical consequences however. No patient experienced severe renal toxicity.

Conclusions

Personalized PRRT makes it possible to safely increase tumour irradiation in the majority of patients. Our first results indicate a favourable tolerance profile, which appears similar to that of the empiric regime. The response rates are promising, in particular in patients with NET of pancreatic origin.

Keywords

Personalized Peptide receptor radionuclide therapy 177Lu-octreotate Dosimetry Neuroendocrine tumours 

Notes

Acknowledgements

We thank Anna Celler, Ph.D. (Physicist, University of British Columbia, Vancouver, Canada) and her students for their ongoing collaboration on quantitative SPECT and dosimetry methods. We are grateful to the nurses and nuclear medicine technologists at the CHU de Québec – Université Laval who provided care for our patients, as well as to the Gastrointestinal Oncology Multidisciplinary Team at CHU de Québec – Université Laval for supporting our PRRT program, in particular to Dr. Jean-François Ouellet (Surgeon) and Dr. Félix Couture (haematologist-oncologist). Finally, we would like to thank all our referring physicians for their trust, in particular Dr. Daniel Rayson (Medical Oncologist, Dalhousie University, Halifax, Canada).

Funding

M.D.P. was supported by a Merit Scholarship for Foreign Students from the Ministère de l’éducation et de l’enseignement supérieur du Québec. J.M.B. is supported by a Clinical Research Scholarship from the Fonds de recherche du Québec – Santé. This work was funded by the Canadian Institutes of Health Research (CIHR) operating grant MOP-142233 to J.M.B.

Compliance with ethical standards

Conflicts of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Supplementary material

259_2018_4209_MOESM1_ESM.docx (60 kb)
ESM 1 (DOCX 60 kb)

References

  1. 1.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.  https://doi.org/10.1056/NEJMoa1607427.CrossRefGoogle Scholar
  2. 2.
    Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925–33.  https://doi.org/10.1007/s00259-013-2677-3.CrossRefGoogle Scholar
  3. 3.
    Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.  https://doi.org/10.1200/JCO.2007.15.2553.CrossRefGoogle Scholar
  4. 4.
    Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.  https://doi.org/10.1007/s00259-011-1902-1.CrossRefGoogle Scholar
  5. 5.
    Sandström M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41.  https://doi.org/10.2967/jnumed.112.107524.CrossRefGoogle Scholar
  6. 6.
    Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480–9.  https://doi.org/10.1007/s00259-017-3678-4.CrossRefGoogle Scholar
  7. 7.
    Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490–500.  https://doi.org/10.1007/s00259-017-3688-2.CrossRefGoogle Scholar
  8. 8.
    Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11:56–66.  https://doi.org/10.1102/1470-7330.2011.0012.CrossRefGoogle Scholar
  9. 9.
    Sandström M, Ilan E, Karlberg A, Johansson S, Freedman N, Garske-Roman U. Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015;2(1):24.  https://doi.org/10.1186/s40658-015-0127-y. CrossRefGoogle Scholar
  10. 10.
    van Vliet EI, Krenning EP, Teunissen JJ, Bergsma H, Kam BL, Kwekkeboom DJ. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2013;54(10):1689–96.  https://doi.org/10.2967/jnumed.112.117408.CrossRefGoogle Scholar
  11. 11.
    Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52(9):1361–8.  https://doi.org/10.2967/jnumed.111.087932.CrossRefGoogle Scholar
  12. 12.
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.  https://doi.org/10.1200/JCO.1998.16.1.139.CrossRefGoogle Scholar
  13. 13.
    Fayers P, Bottomley A. Group EQoL, quality of life U. quality of life research within the EORTC—the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38(Suppl 4):S125–33.CrossRefGoogle Scholar
  14. 14.
    Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847–56.  https://doi.org/10.1007/s00259-008-0778-1.CrossRefGoogle Scholar
  15. 15.
    Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging. 2010;37(10):1869–75.  https://doi.org/10.1007/s00259-010-1483-4.CrossRefGoogle Scholar
  16. 16.
    Kesavan M, Claringbold PG, Turner JH. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology. 2014;99(2):108–17.  https://doi.org/10.1159/000362558.CrossRefGoogle Scholar
  17. 17.
    Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27(9):561–9.  https://doi.org/10.1089/cbr.2012.1276.CrossRefGoogle Scholar
  18. 18.
    Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55(8):1248–52.  https://doi.org/10.2967/jnumed.114.138834.CrossRefGoogle Scholar
  19. 19.
    Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52(12):1886–90.  https://doi.org/10.2967/jnumed.111.095778.CrossRefGoogle Scholar
  20. 20.
    Chan HS, Konijnenberg MW, Daniels T, Nysus M, Makvandi M, de Blois E, et al. Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine. EJNMMI Res. 2016;6(1):83.  https://doi.org/10.1186/s13550-016-0240-5. CrossRefGoogle Scholar
  21. 21.
    Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54(1):37–51.Google Scholar
  22. 22.
    Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75–81.  https://doi.org/10.2967/jnumed.117.193706.CrossRefGoogle Scholar
  23. 23.
    Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212–25.  https://doi.org/10.1007/s00259-009-1216-8.CrossRefGoogle Scholar
  24. 24.
    Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys. 2018;5(1):25.  https://doi.org/10.1186/s40658-018-0224-9 CrossRefGoogle Scholar
  25. 25.
    Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23(5):L17–23.  https://doi.org/10.1530/ERC-15-0543.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Michela Del Prete
    • 1
    • 2
    • 3
    • 4
  • François-Alexandre Buteau
    • 1
    • 2
  • Frédéric Arsenault
    • 1
    • 2
    • 3
    • 4
  • Nassim Saighi
    • 1
    • 2
    • 3
    • 4
  • Louis-Olivier Bouchard
    • 1
    • 5
  • Alexis Beaulieu
    • 1
    • 2
  • Jean-Mathieu Beauregard
    • 1
    • 2
    • 3
    • 4
    Email author
  1. 1.Department of Radiology and Nuclear MedicineUniversité LavalQuebec CityCanada
  2. 2.Division of Nuclear Medicine, Department of Medical ImagingCHU de Québec – Université LavalQuebec CityCanada
  3. 3.Cancer Research CenterUniversité LavalQuebec CityCanada
  4. 4.Oncology BranchCHU de Québec – Université Laval Research CenterQuebec CityCanada
  5. 5.Division of Radiology, Department of Medical ImagingCHU de Québec – Université LavalQuebec CityCanada

Personalised recommendations